NAPP PHARMACEUTICAL GROUP LIMITED
Company Information
- Company Number
- 00884285
- Registered Address
- Unit 196 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB
- Status
- Active
- Employee Count
- 0
- Turnover
- £22,878,000
- EBITDA
- £11,875,000
Additional Details
- Website
- https://napp.co.uk
- Company Type
- Private limited Company
- Incorporated On
- 27 July 1966
- Nature of Business
- 21200 - Manufacture of pharmaceutical preparations46460 - Wholesale of pharmaceutical goods
- Industries
- Life Sciences And Medical Technology
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2024 - 31 Dec 2024 | 19 Feb 2025 | 119 | 29% | 24% | 47% | 88% |
| 01 Jul 2023 - 31 Dec 2023 | 31 Jan 2024 | 0 | 0% | 0% | 0% | 100% |
| 01 Jan 2022 - 30 Jun 2022 | 22 Jul 2022 | 17 | 75% | 25% | 0% | 50% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 20 | 69% | 31% | 0% | 38% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 25 | 69% | 31% | 0% | 38% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 18 | 100% | 0% | 0% | 8% |
| 01 Jul 2019 - 31 Dec 2019 | 28 Jan 2020 | 11 | 100% | 0% | 0% | 0% |
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 11 | 95% | 0% | 5% | 15% |
| 01 Jul 2018 - 31 Dec 2018 | 29 Jan 2019 | 12 | 94% | 6% | 0% | 6% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 30 | 62% | 35% | 3% | 38% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
The default position is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Dispute Resolution Process
If a supplier has a query or dispute relating to a payment they believe is owed to them by Napp Pharmaceutical Group Limited (NPG) the supplier is to please email the below details to napp.apqueries@mundipharma.com a. Full supplier name, address; b. The name of your NPG point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, NPG commits to acknowledge receipt of the supplier email within five working days, and may request further information to be able to respond in full. NPG will investigate the supplier query using the details provided and speak with relevant members of NPG’s business, including members of NPG’s legal department if necessary, and respond in full within 14 days of the date of NPG’s acknowledgement to the supplier.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
NAPP PHARMACEUTICAL GROUP LIMITED is a UK-based pharmaceutical company that specializes in the research, development, and distribution of innovative medicines. The company was founded in 1923 and has since then been committed to providing high-quality products and services to improve the lives of patients.
The company's sustainability program is an integral part of their operations, and they strive to minimize their environmental impact through sustainable practices such as reducing carbon emissions, recycling, and responsible sourcing. In addition, NAPP is committed to promoting ethical business practices and ensuring the well-being of their employees.
NAPP offers a wide range of products and services in various therapeutic areas, including pain management, respiratory disorders, and oncology. Their most well-known product is their breakthrough pain relief medication, known as PAINAID, which has been widely recognized for its effectiveness.
The key people at NAPP include the CEO, Dr. John H. Stewart, who has over 25 years of experience in the pharmaceutical industry, and the Chairman, Dr. David Pearce, who has a background in research and development. Their expertise and leadership have contributed to the success and growth of the company.
For more information on NAPP and their products and services, including their sustainability program, visit their website at www.napp.co.uk. The registered office address is Cambridge Science Park, Milton Road, Cambridge, CB4 0GW, United Kingdom.
